PPAR𝜸 Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice

Figure 1

Effect of Rosi treatment on the urinary output of prostanoids and urine volume in db/db mice. (a) Urinary PGE2 output. (b) Urinary PGD2 output. (c) Urinary TXB2 output. (d) Urinary 6-keto-PGF1α output. (e) Urinary volume. 𝑁=4-5 in each group. Data are mean ± SE.

(a)

(b)

(c)

(d)

(e)